

IN RE: GLUCAGON-LIKE	:	CIVIL ACTION
PEPTIDE-1 RECEPTOR AGONISTS	:	
(GLP-1 RAS) PRODUCTS	:	
LIABILITY LITIGATION	:	
	:	MDL No. 3094
	:	24-md-3094
THIS DOCUMENT RELATES TO:	:	
	:	HON. KAREN SPENCER MARSTON
ALL ACTIONS/ALL CASES	:	

Second Amended Scheduling Order for Cross Cutting Issues 2 and 3

October 24, 2025	Deadline for fact discovery as to Eli Lilly ¹
November 21, 2025	Deadline for fact discovery as to Novo Nordisk
December 19, 2025	Deadline for Plaintiffs to serve expert reports ²
January 30, 2026	Deadline for Defendants to serve expert reports
February 9, 2026	Deadline for Plaintiffs to serve rebuttal expert reports

² Plaintiffs agree to serve separate expert reports, even if the same expert, for Defendants Eli Lilly and Novo Nordisk, thus separating the factual and opinion discussions for each Defendant.

March 27, 2026	Deadline for all parties to complete expert depositions
April 14, 2026	Deadline for the submission of motions to exclude expert opinions under Rule 702 and initial briefs
April 16, 2026	Deadline for the submission of summary judgment motions and initial briefs ³
May 20, 2026	Deadline for the submission of briefs in opposition to Rule 702 motions
June 2, 2026	Deadline for the submission of briefs in opposition to summary judgment motions
June 10, 2026	Deadline for the submission of reply briefs in support of Rule 702 motions
July 10, 2026	Deadline for the submission of reply briefs in support of summary judgment motions

IT IS SO ORDERED.

/s/Karen Spencer Marston

KAREN SPENCER MARSTON, J.

³ As discussed at the September 30, 2025 and October 3, 2025 hearings, Novo Nordisk reserves the right to defer filing motions related to preemption until such time as the record is closed in the ongoing activity related to the 483 investigation.